Aehr Test Systems: The Valuation Leaves Little Room For Error
Aehr Test Systems is transitioning from silicon carbide to AI-focused testing, reporting record bookings and a strong backlog supporting FY2027 growth.
Archived explainer. For the current picture see today's AEHR page.
AEHR TEST SYS (AEHR) is up +24.87% in the latest session. Our newswire has captured 2 stories on AEHR across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 70/100).
Aehr Test Systems stock surged by 24.87% to $96.62 on Wednesday, driven by a bullish outlook for fiscal year 2027 and strong recent performance. The company is shifting its focus from silicon carbide to AI-driven testing, a move that has generated optimism among investors. Record bookings and a robust backlog have further supported expectations for growth.
The stock opened at $81.48, a 5.3% gap up from the previous close, and climbed steadily throughout the session. The price reached a high of $96.90 at 11:10 AM ET before closing near the top of the range at $96.71. The rally was fueled by management’s optimistic guidance for FY2027, which reflects confidence in the company’s strategic shift and market demand for its AI testing solutions. This has led to a 11.6% weekly gain, with traders increasing their exposure to the stock.
Retail traders on social platforms have noted the stock as oversold, and recent coverage from Seeking Alpha has emphasized the valuation challenges and potential for growth. Despite recent insider sales, the broader market environment appears to be supporting risk-on sentiment, with the Dow rising on producer inflation data and investor sentiment improving.
The stock’s intraday volume of 1.9 million shares is 0.7 times the 3-month average, indicating moderate participation. The price is currently within its 52-week range of $14.99 to $126.62, with a market cap of $2.6 billion. The company remains unprofitable with a trailing twelve-month EPS of -0.23 and a net margin of -14.3%. Revenue has declined by 15.2% over the same period. Recent insider transactions include three sales totaling $2.6 million, with no insider buying reported in the last 90 days.
The company has not disclosed an upcoming earnings date. Investors should monitor the breadth of coverage and any further guidance from management regarding the AI testing transition and FY2027 performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Aehr Test Systems is transitioning from silicon carbide to AI-focused testing, reporting record bookings and a strong backlog supporting FY2027 growth.
Shares in Aehr Test Systems Inc. (NASDAQ:AEHR) jumped by 11.6 percent week-on-week, as investors increased their exposure after management posted a highly optimistic outlook for fiscal year 2027, thanks to the continued strong demand for semiconductor testing. In an updated report last week, the company said that it is targeting to grow its revenues during […]
More on AEHR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AEHR move explainers: 2026-07-28 · 2026-07-24 · 2026-07-22 · 2026-07-21 · 2026-07-20 · 2026-07-17 · 2026-07-16 · 2026-07-14